Hocoma

Hocoma occupies a specialized position in rehabilitation robotics, combining medical-device manufacturing with therapy workflows for neurological and movement disorders. Its portfolio covers several treatment stages and modalities: Lokomat for intensive gait rehabilitation, Erigo Pro for early mobilization, Andago V2.0 for gait training during daily-living activities, and Armeo systems for arm-and-hand therapy. Hocoma’s positioning is also broader than hardware alone: it emphasizes clinical training, certification, research collaboration, clinical integration, technical service, and ongoing user education. That service layer may support adoption in hospitals and rehabilitation centers where implementation expertise is as important as equipment capability. The company’s categories—Health Care, Robotics, and Therapeutics—reflect a cross-disciplinary model spanning regulated medical technology and robotics.

Hocoma’s trajectory reflects a long product-development cycle rather than a venture-funded scaling story. Founded in 1996 by Gery Colombo, Matthias Jörg, and Peter Hostettler, the company developed from a Swiss medical-technology business into an international rehabilitation-device organization. The Sep 2, 2016 acquisition announcement by DIH marked a major ownership inflection point. Later descriptions place the company above 160 employees across headquarters near Zurich and subsidiaries in the United States, Singapore, and Slovenia, indicating expansion beyond its original Swiss base. Product breadth is another growth indicator: the portfolio spans gait rehabilitation, early mobilization, balance-oriented therapy, and upper-limb treatment through Lokomat, Erigo, Andago, and Armeo platforms. Market visibility increased during 2024 and 2025 as Hocoma was repeatedly referenced in coverage of rehabilitation robotics, exoskeletons, wearable medical robots, and related markets. The evidence therefore supports durable international operations and portfolio expansion, but not a precise forward growth rate.